Management of Seizures and Cognitive Decline in Oligodendroglioma Patients

Primary Seizure Management Strategy

The American Academy of Neurology recommends levetiracetam as the preferred first-line antiepileptic drug due to its efficacy, favorable side-effect profile, and lack of drug interactions with chemotherapy agents 1
Lamotrigine serves as an effective alternative to levetiracetam, though it requires several weeks of gradual titration to reach therapeutic levels 1
Third-generation AEDs, such as levetiracetam and lamotrigine, are strongly preferred over first-generation drugs that induce hepatic metabolism and interfere with chemotherapy 1
The National Institute of Neurological Disorders and Stroke advises avoiding enzyme-inducing anticonvulsants, such as phenytoin, carbamazepine, and phenobarbital, as they interfere with chemotherapy metabolism and have worse side-effect profiles 1

The American Epilepsy Society recommends checking serum drug levels first to assess compliance and therapeutic dosing 1
Increasing to therapeutic levels is recommended if the patient is on subtherapeutic doses of their current AED 1
Adding a second non-enzyme-inducing AED is recommended rather than switching agents abruptly if already on therapeutic monotherapy with persistent breakthrough seizures 1
The European Academy of Neurology suggests considering lacosamide as add-on therapy for patients whose seizures are not controlled by monotherapy 1

The National Comprehensive Cancer Network recommends obtaining repeat brain MRI immediately to assess for recurrent tumor growth if there is worsening of a pre-existing seizure disorder 1
Pseudoprogression can occur, particularly within the first 3 months after chemoradiotherapy, and may require repeat imaging in 4-8 weeks to confirm true progression, as noted by the European Society for Medical Oncology 2

The International Psycho-Oncology Society recommends offering counseling by specialized psychologists or nurses and palliative care specialists, as recommended for all non-curable diseases 2
Assessing the need for occupational, speech, and physical therapy as well as counseling for social support is recommended by the American Cancer Society 2

The European Society for Medical Oncology emphasizes the importance of evaluation by a specialized multidisciplinary team for optimal management 3, 4
Special consideration should be given to performance status and neurological function when making treatment decisions, as recommended by the National Cancer Institute 3, 4

The National Comprehensive Cancer Network suggests considering five therapeutic options: surgery, systemic chemotherapy, local chemotherapy, second-line radiotherapy, or palliative care without specific anticancer treatment 5, 6, 7, 8
The American Society of Clinical Oncology recommends that the decision to perform surgery should only be taken after multidisciplinary consultation 5, 6, 7, 8
Temozolomide or nitrosourea-based regimens may be appropriate, especially if there was a long interval since prior radiation and/or good response to prior radiation, as noted by the National Institute of Neurological Disorders and Stroke 9